🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Any debate about the low percentage of pts who underwent ASCT in the SOC arm of ZUMA-7 misses the point that a low percentage of pts undergo ASCT due to toxicity or lack of response with salvage chemotherapy. Impressive data. Frederick L. Locke #ASH21 #lymsm

Women in Lymphoma at ASH21. My great @sloan_kettering colleagues ⭕Blaise13💙 Connie Batlevi Ariela Noy

Sunrise in New York City seen from Newark Liberty Airport, Monday morning #newyorkcity #nyc #newyork United Airlines #sunrise A Great Big City

We have a fully funded postdoctoral fellow position available. The candidate will investigate molecular drivers of T cell lymphomas using clinically relevant mouse models and patient sample correlatives from clinical trials! choilaboratory.northwestern.edu

LATER at 6:00PM EST: LRF grantee Elizabeth Brem, MD of UCI Health to present findings from phase III study of R-miniCHOP w/ oral Azacitidine (CC-486) to treat various B-cell #lymphomas in patients newly diagnosed age 75 or older. #ASH21 Read more: ow.ly/hLLY50H9nK9

PTCL updates @ #ASH2021 - 133 Herrera: upfront BV-CHEP for CD30+ (≥1%), ORR/CR 91/80%! Challenger to BV-CHP? - 134 Chiappella: upfront Ro-CHOEP, did not meet 18m 70% PFS obj. but 81% 18m PFS in TFH. Subpopulations critical in trial design! 1/5

Our perspective on EZH2 biology and therapeutic targeting @DrStephenAnsell ⁦Mayo Clinic ⁦Mayo Clinic Hematology-Oncology Fellowship⁩ Tazemetostat: a treatment option for relapsed/refractory follicular lymphoma: Expert Opinion on Pharmacotherapy: Vol 0, No 0 tandfonline.com/doi/full/10.10…

Models of inter-patient heterogeneity can predict clinical efficacy of drug combinations for advanced incurable cancers, but curative therapy is more complex. We now have models of intra- and inter-tumor heterogeneity, and they match the first success in 20 yrs for 1st line DLBCL

Working with #valentinanardi and #david_weinstock, Katie Lee found recurrent jak2 fusions in aggressive skin lymphomas. her work has launched a clinical trial at NU and MSKCC! Primary cytotoxic T-cell lymphomas harbor recurrent targetable alterat... sciencedirect.com/science/articl…

Well worth a listen for anyone involved in medical education #meded Calvin Chou bravo! open.spotify.com/episode/2jyZFy…

What New York City is doing now is what the US should have done for all Americans a long time ago: free KN95 masks and rapid antigen tests 👍👏

The ECHELON-2 Trial: 5-year results of a randomized, phase 3 study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma #lymphoma #lymsm bit.ly/3Jd6re2

While this is wonderful, it is news primarily because something as simple as stating and defending scientific principles will likely result in death threats for Francis Collins, all because one of the two major political parties is committed to demonizing empiricism.

Our review of a challenging disease with Zach E-P @DrCraigSauter and others: Current Treatment of Peripheral T-cell Lymphoma cancernetwork.com/view/journal-c… via CancerNetwork®

2020 was a rough year for many people. Towards the end of the year, it was the time that I was diagnosed with an acoustic neuroma and subsequently underwent surgery. 🧵 huffpost.com/entry/brain-ca…

Reinstalled the Twitter app and breaking my silence to highly recommend this episode. If you’ve dealt with #impostersyndrome (irrespective of your profession/field) like I have and continue to, I think you’ll find this conversation really worthwhile. podcasts.apple.com/us/podcast/we-…

Capitalizing on my two great talents, op-eds and bad puns, I've created a section on my website called Op-Education. The point, you might have already guessed, is to give people guidance on how to write a smart commentary piece. getopinioned.com/opeducation/cr…